Sarah Jaw‐Tsai - Concepedia

Concepedia

Author

Sarah Jaw‐Tsai

Clovis Oncology (United States)

Also Known As

Jaw-Tsai, S, Jaw-Tsai, S., S Jaw-Tsai, S. Jaw-Tsai, Sarah Jaw-Tsai, Sarah Jaw‐Tsai, Sarah S Jaw-Tsai, Sarah S. Jaw-Tsai, Sarah S. Jaw-Tsai

62

Publications

2.1K

Citations

17

H-Index

42

Concepts

All Affiliations

Clovis Oncology (United States)The Barbara Ann Karmanos Cancer Institute Dana-Farber Cancer Institute Wayne State University Sarah Cannon

SJ

About

Sarah Jaw‐Tsai is an author at Clovis Oncology (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	514
2	Health Sciences	3	3	83
3	Biochemistry	3	3	168
4	Chemistry	1	1	10
5	Diabetes	1	1	14

Sarah Jaw‐Tsai

×

21

Publications

2.1K

Citations

17

H-Index

	Year	Citations
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman, New England Journal of Medicine	2015	660
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma, Cancer Discovery	2013	622
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Lecia V. Sequist, Jean‐Charles Soria, Shirish M. Gadgeel, Journal of Clinical Oncology PathologyPharmacotherapyT790m MutationFirst-in-human EvaluationDermatology	2014	143
Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors Kathy Steece‐Collier, Leslie K. Chambers, Sarah Jaw‐Tsai, Experimental Neurology BiochemistryFunctional SelectivityMedicineAntiparkinsonian ActionsMechanism Of Action	2000	136
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours Richard H. Wilson, TR Jeffry Evans, Mark R. Middleton, British Journal of Cancer	2017	76
CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents Frank S. Menniti, Martin J. Pagnozzi, Paul Butler, Neuropharmacology MedicineNeuropharmacologyNeuroscienceMolecular NeurobiologyPharmacology	2000	56
First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. Lecia V. Sequist, Jean‐Charles Soria, Shirish M. Gadgeel, Journal of Clinical Oncology PathologyPharmacotherapyT790m MutationFirst-in-human EvaluationDermatology	2013	42
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors Geoffrey I. Shapiro, Rebecca Kristeleit, Howard A. Burris, Clinical Pharmacology in Drug Development	2018	41
Evaluation of <i>in vitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor Mingxiang Liao, Sarah Jaw‐Tsai, Jeri Beltman, Xenobiotica	2020	38
Metabolism, Pharmacokinetics, and Excretion of a Highly Selective N-Methyl-d-aspartate Receptor Antagonist, Traxoprodil, in Human Cytochrome P450 2D6 Extensive and Poor Metabolizers Kim A. Johnson, Ajit Shah, Sarah Jaw‐Tsai, Drug Metabolism and Disposition	2003	37

Page 1